Analysis of Azithromycin adverse events in COVID-19 Patients reported to Iraqi Pharmacovigilance center in 2020
DOI:
https://doi.org/10.32947/ajps.v22i3.887Keywords:
Corona Virus, Covid-19, Azithromycin, Pharmacovigilance, Adverse events.Abstract
Azithromycin is an antibiotic that belongs to the macrolide family used in a wide variety of bacterial diseases. However, it has been proposed as a potential therapy for the treatment of SARS-CoV-2 pneumonia (off-label use) given for its antiviral and
immunomodulatory activity. Never-theless, its role in the treatment of COVID-19 remains unclear. Azithromycin has a well-characterized safety profile. However, its use outside the approved indication needs further follow up to ensure that the benefit-risk balance remains positive. One method to look for new/ changed safety information is through using the information component (IC025) value. IC025 is the lower limit of a 95% credibility interval for the IC. The credibility interval provides information about the stability of a particular IC value: the narrower the interval, the higher the stability.
Objective:
Study the submitted adverse events reports of Azithromycin to the Iraqi Pharmacovigilance center and compare the occurrence of these reported adverse events in Iraq to the internationally reported cases during 2020COVID-19 pandemic using IC025.
Methodology:
The reported adverse events of Azithromycin to the national Pharmacovigilance database were studied qualitatively (age, gender and seriousness) and quantitatively (using IC025) as a measure of presence of a new/changed safety information related to Azithromycin.
Results:
The total number of reports for Azithromycin were 419, female represent (43%) and male represent (55.8%), and the predominant age groups was from 45-64 years representing (41.1%). The most widely reported adverse events were gastrointestinal disorders (68%), cardiac disorders (14.1%), general disorders and administration site effect (6.9%), and investigations (Interfere with Lab tests) (5.7%). There were 96 drug-adverse reaction combinations. The IC025 value for the most widely reported adverse events showed a comparable value for ECG-QT prolonged (3.6/3.7), Arrhythmia (0.6/0.7). There was a decreased value for palpitation (0.5/0.9) and dyspnea (0.3/0.6). Tachycardia and increased liver enzymes showed an increased value of (2.0/0.1) and (0.5/0.1) respectively.
Conclusion:
Using the IC025 was helpful in finding the increased reporting rate of adverse events compared to the background rate.
References
- Tedros A. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
- Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK, Drakoulis N, Tsatsakis A. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review). Int J Mol Med. 2020 Aug; 46(2):467-488. DOI: https://doi.org/10.3892/ijmm.2020.4608
- Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant infections and COVID-19. Nat Rev Microbiol. 2020;18: 409–10. DOI: https://doi.org/10.1038/s41579-020-0395-y
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020; 130:2620–9. DOI: https://doi.org/10.1172/JCI137244
- Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifiro G. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug Saf. 2020;43: 691–8. DOI: https://doi.org/10.1007/s40264-020-00976-7
- Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza (H1N1) pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo). 2019; 72:759–68. DOI: https://doi.org/10.1038/s41429-019-0204-x
- Andreani J, Le Bideau M, Duflot I, Jardot P, Rollanda C, Boxberger M, et al. In vitro testing of hydroxychloroquine and Azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;25(145):104228. DOI: https://doi.org/10.1016/j.micpath.2020.104228
- Kawamura K, Ichikado K, Suga M, Yoshioka M. Efficacy of Azithromycin for treatment of acute exacerbation of chronic fibrosing interstitial pneumonia: a prospective, open-label study with historical controls. Respiration. 2014; 87:478–84. DOI: https://doi.org/10.1159/000358443
- Cai M, Bonella F, Dai H, Sarria R, Guzman J, Costabel U. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 2013; 218:930–7. DOI: https://doi.org/10.1016/j.imbio.2012.10.014
- Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998 Jun; 54(4):315‐2 DOI: https://doi.org/10.1007/s002280050466
- ICH Steering Committee. Clinical safety data management: definitions and standards for expedited reporting E2A. Accessed 22 Apr 2021.
- Zhao, Y., Zhang, J., Zheng, K. et al. Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS). Drugs - Real World Outcomes 9, 231–241 (2022). DOI: https://doi.org/10.1007/s40801-022-00300-y
Downloads
Published
How to Cite
Issue
Section
License
